4-hydroxy-8-chloro-5-methylcoumarin | 799262-11-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 4-hydroxy-8-chloro-5-methylcoumarin
• 英文别名: 8-Chloro-4-hydroxy-5-methyl-2H-1-benzopyran-2-one；8-chloro-4-hydroxy-5-methylchromen-2-one
• CAS: 799262-11-6
• 化学式: C₁₀H₇ClO₃
• 分子量: 210.617
• InChiKey: OSWOIIRSRFFBPV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxy-8-chloro-5-methylcoumarin 、 乙二醛-1,1-二甲基乙缩醛溶液 以 甲醇 为溶剂， 反应 5.0h， 生成 3-(4-hydroxy-8-chloro-5-methyl-2-oxo-2H-chromene-3-yl)-6-chloro-9-methyl-2-methoxy-2,3-dihydro-4H-furo[3,2-c]chromene-4-one
  参考文献：
  名称：

  Synthesis and Anti-inflammatory Activity of Novel Furochromenes

  摘要：

  A series of variously substituted furochromenes, hemiacetals 2, acetals 3, and rearranged compounds 4, were synthesized from variously substituted 4-hydroxycoumarins and evaluated in several in vitro assays, inhibition of mast cell degranulation induced by the activation of FCE receptor type I or calcium ionophore and leukotriene B-4 (LTB4) inhibition. The most active derivatives, 3p and 4p (8-iso-propyl substitution in coumarin ring) and 3r (5-methyl-8-chloro substitution), showed significant inhibition of mast cell degranulation (Fc epsilon-triggered) and LTB4, and exhibited significant local anti-inflammatory activity in PMA induced ear edema in CD1 mice, with potency equal (compounds 3p and 4p) or better (compound 3r) in comparison with zileuton, a reference drug used. It might be a promising direction for developing novel drugs as potential agents for the treatment of allergies and other inflammatory diseases.

  DOI：

  10.5562/cca2240
• 作为产物：
  描述：

  2-氯-5-甲酚 以12.6%的产率得到4-hydroxy-8-chloro-5-methylcoumarin
  参考文献：
  名称：

  [EN] SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION
  [FR] COMPOSES DE FUROCHROMENE SUBSTITUES A ACTION ANTI-INFLAMMATOIRE

  摘要：

  本发明涉及公式（I）的新化合物，包括所有立体异构体和互变异构体，以及其药用可接受盐和溶剂合物，用于预防和治疗人类的哮喘和其他炎症性疾病和/或情况的过程和反应中间体，以及它们的使用。

  公开号：

  WO2005010006A1

文献信息

• Substituted furochromene compounds of antiinflammatory action
  申请人：Mercep Mladen

  公开号：US20060148890A1

  公开（公告）日：2006-07-06

  The present invention relates to novel compounds of the formula (I) including all stereoisomers and tautomers thereof, to the pharmaceutically acceptable salts and solvates thereof, to the processes and reactive intermediates for their preparation and to their use in the prophylaxis and treatment of asthma and other inflammatory diesases and/or conditions in humans.

  本发明涉及式（I）的新化合物，包括其所有立体异构体和互变异构体、药学上可接受的盐和溶剂合物，以及其制备过程和反应中间体，以及它们在预防和治疗人类哮喘和其他炎症性疾病和/或病况中的用途。
• SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION
  申请人：PLIVA-ISTRAZIVACKI INSTITUT d.o.o.

  公开号：EP1648901A1

  公开（公告）日：2006-04-26
• US7208518B2
  申请人：——

  公开号：US7208518B2

  公开（公告）日：2007-04-24
• [EN] SUBSTITUTED FUROCHROMENE COMPOUNDS OF ANTIINFLAMMATORY ACTION<br/>[FR] COMPOSES DE FUROCHROMENE SUBSTITUES A ACTION ANTI-INFLAMMATOIRE
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005010006A1

  公开（公告）日：2005-02-03

  The present invention relates to novel compounds of the formula (I) including all stereoisomers and tautomers, to the pharmaceutically acceptable salts and solvates thereof, to the processes and reactive intermediates for their preparation and to their use in the prophylaxis and treatment of asthma and other inflammatory diseases and/or conditions in humans.

  本发明涉及公式（I）的新化合物，包括所有立体异构体和互变异构体，以及其药用可接受盐和溶剂合物，用于预防和治疗人类的哮喘和其他炎症性疾病和/或情况的过程和反应中间体，以及它们的使用。
• Synthesis and Anti-inflammatory Activity of Novel Furochromenes
  作者：Ivaylo Jivkov Elenkov、Boška Hrvačić、Stribor Marković、Milan Mesić、Andreja Čempuh Klonkay、Lidija Lerman、Anita Filipović Sučić、Ines Vujasinović、Berislav Bošnjak、Karmen Brajša、Dinko Žiher、Nada Košutić Hulita、Ivica Malnar

  DOI：10.5562/cca2240

  日期：——

  A series of variously substituted furochromenes, hemiacetals 2, acetals 3, and rearranged compounds 4, were synthesized from variously substituted 4-hydroxycoumarins and evaluated in several in vitro assays, inhibition of mast cell degranulation induced by the activation of FCE receptor type I or calcium ionophore and leukotriene B-4 (LTB4) inhibition. The most active derivatives, 3p and 4p (8-iso-propyl substitution in coumarin ring) and 3r (5-methyl-8-chloro substitution), showed significant inhibition of mast cell degranulation (Fc epsilon-triggered) and LTB4, and exhibited significant local anti-inflammatory activity in PMA induced ear edema in CD1 mice, with potency equal (compounds 3p and 4p) or better (compound 3r) in comparison with zileuton, a reference drug used. It might be a promising direction for developing novel drugs as potential agents for the treatment of allergies and other inflammatory diseases.